Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(25%)
Results Posted
0%(0 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
6
75%
Ph phase_3
1
13%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Terminated2
Completed2
unknown1
Recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
Phase 31 (12.5%)

Trials by Status

unknown113%
recruiting113%
terminated225%
completed225%
withdrawn113%
active_not_recruiting113%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

NCT06532539
active_not_recruitingphase_2

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

NCT06143748
withdrawnphase_2

Neoadjuvant Immunotherapy to ESCC

NCT04625543
completedphase_3

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

NCT02459457
completedphase_1

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

NCT01534585
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06532539Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting
NCT06143748Phase 2

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

Active Not Recruiting
NCT04625543Phase 2

Neoadjuvant Immunotherapy to ESCC

Withdrawn
NCT02459457Phase 3

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Completed
NCT01534585Phase 1

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Completed
NCT01704690Phase 2

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Terminated
NCT01444547Phase 2

A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin

Unknown
NCT00818090Phase 2

Paclitaxel and Cisplatin for Thymic Neoplasm

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8